본문으로 건너뛰기
← 뒤로

Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection.

1/5 보강
Neoplasia (New York, N.Y.) 📖 저널 OA 100% 2026 Vol.71() p. 101260
Retraction 확인
출처

Zhao Z, Zheng Z, Jiang S, Zhang L, Tang X

📝 환자 설명용 한 줄

[BACKGROUND] Intratumoral heterogeneity contributes to therapy resistance and immune evasion in breast cancer, making treatment strategies more complex.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Zhao Z, Zheng Z, et al. (2026). Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection.. Neoplasia (New York, N.Y.), 71, 101260. https://doi.org/10.1016/j.neo.2025.101260
MLA Zhao Z, et al.. "Multi-omics analysis unveils tumor heterogeneity and immunotherapy predictive model in breast cancer for precision medicine and early detection.." Neoplasia (New York, N.Y.), vol. 71, 2026, pp. 101260.
PMID 41344266

Abstract

[BACKGROUND] Intratumoral heterogeneity contributes to therapy resistance and immune evasion in breast cancer, making treatment strategies more complex. This study integrates single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and bulk RNA-seq deconvolution to characterize tumor subpopulations and develop a robust prognostic model.

[METHODS] We employed a multi-omics approach combining scRNA-seq, spatial transcriptomics, and bulk RNA-seq data deconvolution to explore the molecular diversity within breast cancer tumors. Tumor subtypes were identified based on distinct gene expression profiles, and functional pathway analysis was conducted to evaluate associations with clinical outcomes, including therapy resistance and immune evasion. Data from TCGA and GEO cohorts were integrated to validate the prognostic and immune-related findings. A CoxBoost+GBM algorithm was used to develop a robust prognostic model for patient survival and immunotherapy response prediction.

[RESULTS] Five distinct tumor subtypes were identified, each with unique functional profiles, underscoring the complexity of breast cancer heterogeneity. Basal-like breast cancer (BLBC) cells were found to play a central role in immune evasion and poor immunotherapy response, with high basal-like cell infiltration correlating with worse survival outcomes. Spatial transcriptomics revealed the widespread presence of BLBC cells across clinical subtypes, including ER+ tumors, suggesting their involvement in therapy resistance. A prognostic model based on CoxBoost+GBM demonstrated strong predictive power for patient survival and immunotherapy efficacy.

[CONCLUSIONS] This study provides a comprehensive view of the genetic and immune determinants of breast cancer heterogeneity, with a focus on BLBC's role in immune escape and treatment resistance. These insights enhance the potential of multi-omics approaches in precision prevention, early detection, and personalized immunotherapy strategies.

🏷️ 키워드 / MeSH

같은 제1저자의 인용 많은 논문 (5)

🟢 PMC 전문 열기